Why NASDAQ:TGTX qualifies as a high growth stock.

A possible breakout setup was detected on TG THERAPEUTICS INC (NASDAQ:TGTX) by our stockscreener. A breakout pattern is formed when a stock consolidates after a strong rise up. We note that this pattern is detected purely based on technical analysis and whether the breakout actually materializes remains to be seen. It could be interesting to keep an eye on NASDAQ:TGTX.

Analyzing the Technical Aspects

ChartMill employs a sophisticated system to assign a Technical Rating to every stock in its analysis. This rating, which ranges from 0 to 10, is determined by carefully assessing multiple technical indicators and properties.

Overall TGTX gets a technical rating of 7 out of 10. This is due to a consistent overall performance, although we see some doubts in the very recent evolution. In the medium time frame things are still looking good.

• The long term trend is positive and the short term trend is neutral. The long term trend gets the benefit of the doubt for now.
• When comparing the yearly performance of all stocks, we notice that TGTX is one of the better performing stocks in the market, outperforming 98% of all stocks.
• TGTX is part of the Biotechnology industry. There are 570 other stocks in this industry. TGTX outperforms 94% of them.
• TGTX is currently trading in the upper part of its 52 week range. The S&P500 Index however is currently trading near a new high, so TGTX is lagging the market slightly.

Our latest full technical report of TGTX contains the most current technical analsysis.

Why is NASDAQ:TGTX a setup?

Besides the Technical Rating, ChartMill also assign a Setup Rating to every stock. This setup score also ranges from 0 to 10 and determines to which extend the stock is consolidating. This is achieved by evaluating multiple short term technical indicators. NASDAQ:TGTX currently has a 8 as setup rating:

TGTX has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is very little resistance above the current price. There is a support zone below the current price at 22.18, a Stop Loss order could be placed below this zone. We notice that large players showed an interest for TGTX in the last couple of days, which is a good sign.

Looking into the high growth metrics of TG THERAPEUTICS INC

• The EPS of TG THERAPEUTICS INC has exhibited growth from one quarter to another (Q2Q), with a 112.0% increase. This underscores the company's ability to generate higher earnings and improve its financial standing.
• TG THERAPEUTICS INC has experienced 357.0% q2q revenue growth, indicating a significant sales increase.
• With impressive 1-year revenue growth of 1.0K%, TG THERAPEUTICS INC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• Over the past 3 months, analysts have adjusted their EPS Estimate for TG THERAPEUTICS INC with a 329.0% change. This highlights the evolving outlook on the company's EPS potential.
• In the most recent financial report, TG THERAPEUTICS INC reported a 112.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• TG THERAPEUTICS INC shows accelerating EPS growth: when comparing the current Q2Q growth of 112.0% to the previous year Q2Q growth of -13.33%, we see the growth rate improving.
• With positive growth in its operating margin over the past year, TG THERAPEUTICS INC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
• TG THERAPEUTICS INC has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
• TG THERAPEUTICS INC demonstrates a strong Return on Equity(ROE) of 53.87%. This indicates the company's ability to generate favorable returns for shareholders and reflects its efficient utilization of capital. TG THERAPEUTICS INC shows promising potential for continued success.
• With a current Debt-to-Equity ratio at 0.58, TG THERAPEUTICS INC showcases its disciplined capital structure. The company's prudent management of debt obligations contributes to its financial stability and long-term sustainability.
• With institutional shareholders at 60.58%, TG THERAPEUTICS INC demonstrates a healthy ownership distribution. This reflects a mix of institutional and individual investors, creating a market environment that may foster increased trading activity and price discovery.
• TG THERAPEUTICS INC has exceeded EPS estimates 3 times in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
• TG THERAPEUTICS INC has exhibited strong Relative Strength(RS) in recent periods, with a current 98.39 rating. This indicates the stock's ability to outperform the broader market and reflects its competitive position. TG THERAPEUTICS INC shows promising potential for continued price momentum.

More ideas for high growth momentum breakouts can be found on ChartMill in our High Growth Momentum Breakout screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.